ABSTRACT
Introduction Healthcare workers are vulnerable to adverse mental health impacts of COVID-19. We assessed prevalence of mental disorders and associated factors during the first wave of the pandemic among healthcare professionals in Spain.
Methods All workers in 18 healthcare institutions (6 AACC) in Spain were invited to a series of online surveys assessing a wide range of individual characteristics, COVID-19 infection status and exposure, and mental health status. Here we report: current mental disorders (Major Depressive Disorder-MDD- [PHQ-8≥10], Generalized Anxiety Disorder-GAD- [GAD-7≥10], Panic attacks, Posttraumatic Stress Disorder –PTSD- [PCL-5≥7]; and Substance Use Disorder –SUD-[CAGE-AID≥2]. Severe disability assessed by the Sheehan Disability Scale was used to identify “disabling” current mental disorders.
Results 9,138 healthcare workers participated. Prevalence of screen-positive disorder: 28.1% MDD; 22.5% GAD, 24.0% Panic; 22.2% PTSD; and 6.2% SUD. Overall 45.7% presented any current and 14.5% any disabling current mental disorder. Healthcare workers with prior lifetime mental disorders had almost twice the prevalence of current disorders than those without. Adjusting for all other variables, odds of any disabling mental disorder were: prior lifetime disorders (TUS: OR=5.74; 95%CI 2.53-13.03; Mood: OR=3.23; 95%CI:2.27-4.60; Anxiety: OR=3.03; 95%CI:2.53-3.62); age category 18-29 years (OR=1.36; 95%CI:1.02-1.82), caring “all of the time” for COVID-19 patients (OR=5.19; 95%CI: 3.61-7.46), female gender (OR=1.58; 95%CI: 1.27-1.96) and having being in quarantine or isolated (OR= 1.60; 95CI:1.31-1.95).
Conclusions Current mental disorders were very frequent among Spanish healthcare workers during the first wave of COVID-19. As the pandemic enters its second wave, careful monitoring and support is needed for healthcare workers, especially those with previous mental disorders and those caring COVID-19 very often.
Competing Interest Statement
EV reports personal fees from Abbott, personal fees from Allergan, personal fees from Angelini, grants from Novartis, grants from Ferrer, grants and personal fees from Janssen, personal fees from Lundbeck, personal fees from Sage, personal fees from Sanofi, outside the submitted work. JDM reports personal fees from Janssen, personal fees and non-financial support from Otsuka, personal fees and non-financial support from Lundbeck, personal fees from Angelini, personal fees and non-financial support from Accord, outside the submitted work. In the past 3 years, RCK received support for epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Ind. Lake Nona Life Project. RCK is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. All other authors reported no conflict of interest.
Funding Statement
This work was supported by Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (Ministerio de Ciencia e Innovación) /FEDER (COV20/00711); ISCIII (Sara Borrell, CD18/00049) (PM); FPU (FPU15/05728) (LB); ISCIII (PFIS, FI18/00012) (BP); Generalitat de Catalunya (2017SGR452).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB Parc de Salut Mar (2020/9203/I)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† The MINDCOVID Working Group is formed by: Jordi Alonso, Itxaso Alayo, Manuel Alonso, Mar Álvarez, Benedikt Amann, Franco F. Amigo, Gerard Anmella, Andres Aragón, Nuria Aragonés, Enric Aragonès, Ana Isabel Arizón, Angel Asunsolo, Alfons Ayora, Laura Ballester, Puri Barbas, Josep Basora, Elena Bereciartua, Inés Bravo, Ignasi Bolibar, Xavier Bonfill, Alberto Cotillas, Andres Cuartero, Concha de Paz, Isabel del Cura, Maria Jesus del Yerro, Domingo Díaz, José Luis Domingo, Jose I. Emparanza, Mireia Espallargues, Meritxell Espuga, Patricia Estevan, M. Isabel Fernandez, Tania Fernandez, Montse Ferrer, Yolanda Ferreres, Giovanna Fico, M. Joao Forjaz, Rosa García-Barranco, J. Manuel García-Torrecillas C. García-Ribera, Araceli Garrido, Elisa Gil, Marta Gómez, Javier Gómez, Ana González-Pinto, Josep Maria Haro, Margarita Hernando, María Giola-Insigna, Milagros Iriberri, Nuria Jiménez, Xavi Jiménez, Amparo Larrauri, Fernando León, Nieves Lopez-Fresneña, Carmen López, Mayte López-Atanes Juan Antonio López-Rodríguez, Germán López-Cortacans, Alba Marcos, Jesús Martín, Vicente Martín, Mercedes Martínez-Cortés, Raquel Martínez-Martínez, Alma D. Martínez de Salazar, Isabel Martínez, Marco Marzola, Nelva Mata, Josep Maria Molina, Juan D. Molina, Emilia Molinero, Philippe Mortier, Carmen Muñoz, Andrea Murru, Jorge Olmedo, Rafael M Ortí, Rafael Padrós, Meritxell Pallejà, Raul Parra, Julio Pascual, José María Pelayo, Rosa Pla, Nieves Plana, Coro Pérez Aznar, Beatriz Pérez-Gómez, Aurora Pérez-Zapata, José Ignacio Pijoan, Elena Polentinos, Beatriz Puértolas, Maria Teresa Puig, Álex Quílez, M. Jesús Quintana, Antonio Quiroga, David Rentero, Cristina Rey, Cristina Rius, Carmen Rodríguez-Blázquez, M. José Rojas, Yamina Romero, Gabriel Rubio, Mercedes Rumayor, Pedro Ruiz, Margarita Sáenz, Jesus Sánchez, Ignacio Sánchez-Arcilla, Ferran Sanz, Consol Serra, Victoria Serra-Sutton, Manuela Serrano, Silvia Sola, Sara Solera, Miguel Soto, Alejandra Tarragoó Natividad Tolosa, Mireia Vázquez, Margarita Viciola, Eduard Vieta, Gemma Vilagut, Sara Yago, Jesus Yañez, Yolanda Zapico, Luis Maria Zorita, Iñaki Zorrilla, Saioa L. Zurbano, and Víctor Perez-Solá.
CONFLICT OF INTEREST STATEMENT EV reports personal fees from Abbott, personal fees from Allergan, personal fees from Angelini, grants from Novartis, grants from Ferrer, grants and personal fees from Janssen, personal fees from Lundbeck, personal fees from Sage, personal fees from Sanofi, outside the submitted work. JDM reports personal fees from Janssen, personal fees and non-financial support from Otsuka, personal fees and non-financial support from Lundbeck, personal fees from Angelini, personal fees and non-financial support from Accord, outside the submitted work. In the past 3 years, RCK received support for epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Ind. Lake Nona Life Project. RCK is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. All other authors reported no conflict of interest.
FUNDING This work was supported by Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (Ministerio de Ciencia e Innovación) /FEDER (COV20/00711); ISCIII (Sara Borrell, CD18/00049) (PM); FPU (FPU15/05728) (LB); ISCIII (PFIS, FI18/00012) (BP); Generalitat de Catalunya (2017SGR452).
Data Availability
The de-identified participant data as well as the study protocol and statistical analysis plan used for this study are available upon reasonable request from the corresponding author (JA) as long as the main objective of the data sharing request is replicating the analysis and findings as reported in this paper.
